Management of cytomegalovirus infection after liver transplantation

doi:10.5500/wjt.v14.i3.93209

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1402)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

HTML

1007

Tables (1-2)

132

Sum=1181

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=139

Sep 18, 2024 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Transplant. Sep 18, 2024; 14(3): 93209
Published online Sep 18, 2024. doi: 10.5500/wjt.v14.i3.93209

Management of cytomegalovirus infection after liver transplantation

Zeynep Burcin Yilmaz, Funda Memisoglu, Sami Akbulut

Zeynep Burcin Yilmaz, Funda Memisoglu, Infectious Diseases and Clinical Microbiology, Inonu University Faculty of Medicine, Malatya 44280, Türkiye

Sami Akbulut, Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Malatya 44280, Türkiye

Author contributions: Yilmaz ZB and Akbulut S performed the majority of the writing and prepared the tables; Yilmaz ZB and Memisoglu F performed data accusation and writing; Yilmaz ZB, Memisoglu F, and Akbulut S designed the outline and coordinated the writing of the paper.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Sami Akbulut, FACS, FICS, MD, PhD, Professor, Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, 10 Elazig Yolu Km, Malatya 44280, Türkiye. akbulutsami@gmail.com

Received: February 21, 2024
Revised: May 5, 2024
Accepted: May 27, 2024
Published online: September 18, 2024
Processing time: 160 Days and 10.5 Hours

Core Tip

Core tip: Cytomegalovirus (CMV) is a significant factor in the development of opportunistic infection complications following liver transplantation. Antiviral prophylaxis and pre-emptive treatment are the most effective approaches for preventing post-transplant CMV infection, as stated by current worldwide standards. CMV-IgG serology is still the standard method for screening both donors and recipients prior to transplantation. When discussing the appropriate management of CMV in solid organ transplant recipients, it is important to examine the balance between the use of immunosuppressants and the risk of infection and disease progression.